10x Genomics Reports Third Quarter 2026 Financial Results

Quarterly losses narrowed as gross margin improved, while nine-month revenue and earnings remained below their prior-year levels.

Rhea-AI Summary

10x Genomics (Nasdaq: TXG) reported third-quarter 2026 revenue of $150.7 million, up 1% from the corresponding period of 2025.

Gross margin rose to 75% from 67%, primarily reflecting lower inventory write-downs and product mix. Operating expenses fell 3% to $129.0 million. Operating loss narrowed to $16.1 million from $32.2 million, while net loss narrowed to $19.4 million from $27.5 million. Basic and diluted loss per share was $0.15 versus $0.22.

The company raised its full-year revenue outlook to $625 million–$635 million from $610 million–$630 million. Excluding non-recurring settlement-related license and royalty revenue in both years, it expects 4%–6% growth over 2025. Cash, cash equivalents and marketable securities totaled $575.7 million at September 30, 2026. Global commercial shipments of Atera began, and the company introduced its Sentira cloud analysis platform.

22 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 15 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Full-year 2026 revenue guidance raised to $625 million–$635 million from $610 million–$630 million.
• Moderate pointThird-quarter revenue increased 1% year over year to $150.7 million.
• Moderate pointThird-quarter gross margin rose to 75% from 67%, reflecting lower inventory write-downs and product mix.
• Moderate pointThird-quarter operating expenses fell 3% to $129.0 million, despite higher litigation expenses.
• Moderate pointThird-quarter operating loss narrowed to $16.1 million from $32.2 million a year earlier.
• Moderate pointThird-quarter net loss narrowed to $19.4 million from $27.5 million a year earlier.

16 minor points

• Minor point. Forward-looking: it has not happened yet and may not happen.Revenue outlook implies 4%–6% growth over 2025, excluding non-recurring settlement-related license and royalty revenue in both years.
• Minor pointThird-quarter basic and diluted loss per share narrowed to $0.15 from $0.22 a year earlier.
• Minor pointCash and cash equivalents increased to $526.187 million at September 30, 2026, from $473.966 million at December 31, 2025.
• Minor pointThird-quarter Single Cell consumables revenue increased to $93.139 million from $92.519 million a year earlier.
• Minor pointThird-quarter Spatial consumables revenue increased to $41.188 million from $35.373 million a year earlier.
• Minor pointThird-quarter services revenue increased to $9.025 million from $8.128 million a year earlier.
• Minor pointThird-quarter United States revenue increased to $82.093 million from $77.246 million a year earlier.
• Minor pointThird-quarter Americas revenue excluding the United States increased to $3.849 million from $2.625 million a year earlier.
• Minor pointThird-quarter China revenue increased to $15.216 million from $15.189 million a year earlier.
• Minor pointNine-month Single Cell consumables revenue increased to $270.484 million from $262.416 million a year earlier.
• Minor pointNine-month Spatial consumables revenue increased to $124.396 million from $103.017 million a year earlier.
• Minor pointNine-month services revenue increased to $28.539 million from $24.255 million a year earlier.
• Minor pointNine-month Americas revenue excluding the United States increased to $10.172 million from $9.044 million a year earlier.
• Minor pointNine-month Europe, Middle East and Africa revenue increased to $115.577 million from $108.253 million a year earlier.
• Minor pointNine-month Asia-Pacific revenue excluding China increased to $39.881 million from $36.699 million a year earlier.
• Minor pointStock-based compensation declined to $23.096 million for the quarter and $71.354 million for nine months, versus $25.264 million and $83.585 million.

Negative

• Moderate pointNine-month revenue declined to $452.546 million from $476.793 million a year earlier.
• Moderate pointNine-month operating loss widened to $52.658 million from $41.444 million a year earlier.
• Moderate pointNine-month net loss widened to $50.826 million from $27.292 million a year earlier.
• Moderate pointNine-month operating expenses increased to $384.260 million from $372.280 million a year earlier.
• Minor pointNine-month basic and diluted loss per share widened to $0.39 from $0.22 a year earlier.

10 minor points

• Minor pointThird-quarter Single Cell instrument revenue declined to $3.782 million from $4.927 million a year earlier.
• Minor pointThird-quarter Spatial instrument revenue declined to $3.076 million from $7.072 million a year earlier.
• Minor pointThird-quarter license and royalty revenue declined to $0.457 million from $0.983 million a year earlier.
• Minor pointThird-quarter Europe, Middle East and Africa revenue declined to $38.753 million from $41.624 million a year earlier.
• Minor pointThird-quarter Asia-Pacific revenue excluding China declined to $10.756 million from $12.318 million a year earlier.
• Minor pointNine-month Single Cell instrument revenue declined to $12.092 million from $16.567 million a year earlier.
• Minor pointNine-month Spatial instrument revenue declined to $13.689 million from $24.744 million a year earlier.
• Minor pointNine-month license and royalty revenue declined to $3.346 million from $45.794 million a year earlier.
• Minor pointNine-month United States revenue declined to $240.895 million from $267.555 million a year earlier.
• Minor pointNine-month China revenue declined to $46.021 million from $55.242 million a year earlier.

News Explained

For the nine months ended September 30, 2026, total revenue was $452,546 thousand versus $476,793 thousand in 2025; products and services revenue was $449,200 thousand versus $430,999 thousand, while license and royalty revenue was $3,346 thousand versus $45,794 thousand. The comparison shows the lower total revenue occurred alongside higher products and services revenue and lower license and royalty revenue.

Argus 15 min delay 67 alerts

-9.73% vs previous close $52.41 last price 1.7x rel. volume Open Argus

Details

Market Reaction – TXG

$49.73 – $67.98 Day Range

$6.83B Mkt Cap at Last Price

On Nov 5, the day this news came out, the latest delayed price for TXG is 9.73% below the previous close. Our momentum scanner has recorded 67 alerts for this stock so far that day. The latest delayed price is $52.41. Relative volume is above average at 1.7x the stock’s average daily volume.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Revenue: $150.7 million (+1%) Gross margin: 75% Operating expenses: $129.0 million +5 more

Revenue

$150.7 million (+1%)

Third quarter 2026, year over year

Gross margin

75%

Third quarter 2026; 67% in the prior-year period

Operating expenses

$129.0 million

Third quarter 2026; down 3% year over year

Operating loss

$16.1 million

Third quarter 2026; $32.2 million in the prior-year period

Net loss

$19.4 million

Third quarter 2026; $27.5 million in the prior-year period

Cash, cash equivalents and marketable securities

$575.7 million

As of September 30, 2026

2026 revenue guidance

$625 million to $635 million

Raised from the previous range of $610 million to $630 million

Revenue growth excluding specified license and royalty revenue

4% to 6%

Full year 2026 over full year 2025, excluding non-recurring patent litigation settlement revenue

Previous Earnings Reports

1 past event · Latest: Aug 06

Same Type 1 event

1. Aug 06

   Q2 earnings

   24h Move

   +14.1%

   Reported $151.0 million revenue, 74% gross margin, and raised 2026 guidance to $610–$630 million.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

marketable securities, stock-based compensation, weighted-average shares

3 terms

marketable securities financial

"Cash and cash equivalents and marketable securities were $575.7 million"

Marketable securities are financial assets — such as publicly traded stocks, bonds, and short-term government bills — that a company can quickly sell for cash at a known price. Investors watch them because they show how much ready cash a company can access without selling core operations, like keeping money in a highly liquid savings account versus being tied up in a house, and they affect short-term risk, financial flexibility, and balance-sheet strength.

stock-based compensation financial

"Includes stock-based compensation expense as follows"

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

View in glossary

weighted-average shares financial

"Weighted-average shares used to compute net loss per share"

Weighted-average shares is the average number of a company’s outstanding shares calculated over a reporting period, adjusted for any stock issuances, repurchases, or splits during that time. Investors use it to fairly compare earnings per share and other per-share metrics, because it smooths out changes in the share count the way an average speed reflects trips of different lengths rather than a single snapshot.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLEASANTON, Calif., Nov. 5, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the third quarter ended September 30, 2026.

Recent Updates

• Revenue was $150.7 million for the third quarter of 2026, representing a 1% increase over the corresponding period of 2025.
• Began global commercial shipments of Atera, with extraordinary early demand translating into ambitious new research programs spanning discovery, translational and biopharma research.
• Introduced Sentira, a cloud analysis platform to help customers turn complex biological datasets into insights, powered by NVIDIA accelerated computing for spatial data processing and Anthropic's Claude for agentic AI analysis of single cell data.

"The biggest highlight of the quarter was the start of commercial shipments of Atera. Enthusiasm for the platform has continued to build, and we are incredibly excited to be putting instruments in customers' hands. We were also encouraged with the results across our broader business, driven by continued strength in consumables," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "As biology is entering a new era of AI and data maximalism, 10x is positioned incredibly well to benefit and to be the key enabler of progress going forward."

Third Quarter 2026 Financial Results

Revenue was $150.7 million for the third quarter of 2026, as compared to $149.0 million for the corresponding period of 2025. Revenue increased 1% over the corresponding period of 2025.

Gross margin was 75% for the third quarter of 2026, as compared to 67% for the corresponding prior year period. The increase in gross margin was primarily due to lower inventory write-downs and changes in product mix.

Operating expenses were $129.0 million for the third quarter of 2026, a 3% decrease from $132.5 million for the corresponding prior year period. The decrease was primarily driven by lower personnel and lab equipment expenses, partially offset by higher litigation expenses.

Operating loss was $16.1 million for the third quarter of 2026, as compared to operating loss of $32.2 million for the corresponding prior year period.

Net loss was $19.4 million for the third quarter of 2026, as compared to net loss of $27.5 million for the corresponding prior year period.

Cash and cash equivalents and marketable securities were $575.7 million as of September 30, 2026.

2026 Financial Guidance 

10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $625 million to $635 million, versus the previous range of $610 million to $630 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in both 2026 and 2025, this represents 4% to 6% growth over full year 2025.

Webcast and Conference Call Information

10x Genomics will host a conference call to discuss the third quarter 2026 financial results, business developments and outlook after market close on Thursday, November 5, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.

About 10x Genomics

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "outlook," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s products, services, business strategy, collaborations and opportunities; the commercial launch of, demand for and customer adoption of Atera; the capabilities, availability and expected benefits of Sentira, including its use of third-party accelerated computing and artificial intelligence technologies; the role of artificial intelligence in advancing biological research and 10x Genomics, Inc.'s ability to benefit from that trend; continued demand for consumables; and 10x Genomics, Inc.'s financial performance and results of operations, including expectations regarding revenue, revenue growth and guidance. These statements are based on management's current expectations, forecasts, beliefs, estimates, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2025 filed on February 12, 2026 and the company's quarterly report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the U.S. Securities and Exchange Commission ("SEC"), and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

10x Genomics, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data)
	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Products and services revenue	$      150,210		$      148,019		$      449,200		$      430,999
License and royalty revenue	457		983		3,346		45,794
Revenue (1)	150,667		149,002		452,546		476,793
Cost of products and services revenue (2)	37,740		48,695		120,944		145,957
Gross profit	112,927		100,307		331,602		330,836
Operating expenses:
Research and development (2)	52,929		57,194		166,567		182,663
Selling, general and administrative (2)	76,055		75,355		221,093		239,517
Gain on settlement	—		—		(3,400)		(49,900)
Total operating expenses	128,984		132,549		384,260		372,280
Loss from operations	(16,057)		(32,242)		(52,658)		(41,444)
Other income (expense):
Interest income	5,018		5,199		14,829		13,156
Interest expense	—		3		—		—
Other income (expense), net	(7,437)		(1,165)		(12,139)		3,574
Total other income (expense)	(2,419)		4,037		2,690		16,730
Loss before provision for income taxes	(18,476)		(28,205)		(49,968)		(24,714)
Provision for (benefit from) income taxes	949		(733)		858		2,578
Net loss	$      (19,425)		$      (27,472)		$      (50,826)		$      (27,292)
Net loss per share, basic and diluted	$         (0.15)		$         (0.22)		$         (0.39)		$         (0.22)
Weighted-average shares used to compute net loss per share, basic and diluted	130,805,838		125,502,291		129,570,736		123,965,205

 

(1)	The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company's Visium, Xenium and Atera products:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Instruments
Single Cell	$        3,782		$        4,927		$       12,092		$       16,567
Spatial	3,076		7,072		13,689		24,744
Total instruments revenue	6,858		11,999		25,781		41,311
Consumables
Single Cell	93,139		92,519		270,484		262,416
Spatial	41,188		35,373		124,396		103,017
Total consumables revenue	134,327		127,892		394,880		365,433
Services	9,025		8,128		28,539		24,255
Products and services revenue	150,210		148,019		449,200		430,999
License and royalty revenue	457		983		3,346		45,794
Total revenue	$      150,667		$      149,002		$      452,546		$      476,793

 

(1)	The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Americas
United States*	$       82,093		$       77,246		$      240,895		$      267,555
Americas (excluding United States)	3,849		2,625		10,172		9,044
Total Americas	85,942		79,871		251,067		276,599
Europe, Middle East and Africa	38,753		41,624		115,577		108,253
Asia-Pacific
China	15,216		15,189		46,021		55,242
Asia-Pacific (excluding China)	10,756		12,318		39,881		36,699
Total Asia-Pacific	25,972		27,507		85,902		91,941
Total revenue	$      150,667		$      149,002		$      452,546		$      476,793
* Includes license and royalty revenue.

 

(2)      Includes stock-based compensation expense as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2026		2025		2026		2025
Cost of revenue	$        2,157		$        2,011		$        5,911		$        6,481
Research and development	8,940		11,318		30,168		38,037
Selling, general and administrative	11,999		11,935		35,275		39,067
Total stock-based compensation expense	$       23,096		$       25,264		$       71,354		$       83,585

 

10x Genomics, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands)
	September 30, 2026		December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$      526,187		$      473,966
Marketable securities	49,493		49,443
Accounts receivable, net	55,701		47,013
Other receivables	3,055		35,480
Inventory	64,629		56,341
Prepaid expenses and other current assets	19,566		22,208
Total current assets	718,631		684,451
Property and equipment, net	210,239		226,711
Operating lease right-of-use assets	54,759		60,450
Goodwill	6,918		4,511
Intangible assets, net	58,663		62,329
Other noncurrent assets	13,919		2,913
Total assets	$   1,063,129		$   1,041,365
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$       21,594		$       12,733
Accrued compensation and related benefits	39,657		42,500
Accrued expenses and other current liabilities	32,181		39,971
Deferred revenue	22,956		23,902
Operating lease liabilities	11,946		10,985
Contingent consideration, current	12,036		23,363
Total current liabilities	140,370		153,454
Contingent consideration, noncurrent	5,842		1,237
Operating lease liabilities, noncurrent	63,846		73,376
Deferred revenue, noncurrent	8,530		10,501
Other noncurrent liabilities	6,505		6,471
Total liabilities	225,093		245,039
Stockholders' equity:
Preferred stock	—		—
Common stock	2		2
Additional paid-in capital	2,399,254		2,306,690
Accumulated deficit	(1,561,417)		(1,510,591)
Accumulated other comprehensive income	197		225
Total stockholders' equity	838,036		796,326
Total liabilities and stockholders' equity	$   1,063,129		$   1,041,365

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-reports-third-quarter-2026-financial-results-302931240.html

SOURCE 10x Genomics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were 10x Genomics' third-quarter 2026 revenue and earnings?

10x Genomics reported $150.7 million in revenue and a $19.4 million net loss for the third quarter of 2026. Revenue increased 1% year over year, while net loss narrowed from $27.5 million. Basic and diluted loss per share was $0.15, compared with $0.22 a year earlier.

What is 10x Genomics' updated 2026 revenue guidance?

10x Genomics expects full-year 2026 revenue of $625 million to $635 million, raised from $610 million to $630 million. Excluding non-recurring license and royalty revenue related to patent litigation settlements in both 2026 and 2025, the outlook represents 4% to 6% growth over full-year 2025.